A Retrospective, International Study for Off Label Biologic Use in the Treatment of Hypereosinophilic Syndromes
Latest Information Update: 23 Apr 2021
At a glance
- Drugs Alemtuzumab (Primary) ; Benralizumab (Primary) ; Dupilumab (Primary) ; Mepolizumab (Primary) ; Omalizumab (Primary) ; Reslizumab (Primary)
- Indications Hypereosinophilic syndrome
- Focus Adverse reactions; Therapeutic Use
- 23 Apr 2021 New trial record
- 01 Mar 2021 Interim Results presented at the 2021 Annual Meeting of the American Academy of Allergy, Asthma and Immunology